Catalyst
Slingshot members are tracking this event:
Alexion (ALXN) Presents Data from Phase 1/2 Dose-Escalation Study of ALXN1210 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ALXN |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 04, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 1/2, Dose-escalation Study, Alxn1210, Paroxysmal Nocturnal Hemoglobinuria, Pnh
